{"changeSha256":"f10e80de472e0267eada8d272af5f9315f4f1f495619bfcec7cc2f3e691af902","changedAt":"2026-11-14","changedFields":[{"after":"Large randomized trials in China report weight loss and lower blood sugar. The Chinese approval is reported by local-government sources, not the national approval decision or complete prescribing information. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels.","before":"These are attributable local-government reports, not the national approval decision or complete prescribing information. The national decision and exact indication conditions remain to be reconciled. This account does not establish approval in the United States or other jurisdictions.","field":"Evidence note"},{"after":"ctg-nct07718126-v1, sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-40421736, journal-pmid-41407860, journal-pmid-42628555, ctg-observation-nct06124807-2026-04-21-5c8024d25060, ctg-observation-nct07469800-2026-05-27-81ca4ac5542c, ctg-observation-nct06862908-2026-09-22-928b8a087806","before":"ctg-nct07718126-v1, sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025","field":"Cited source records"},{"after":"West China Hospital [sources: ctg-nct07718126-v1]; Innovent Biologics [sources: ctg-observation-nct07469800-2026-05-27-81ca4ac5542c]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]","before":"West China Hospital [sources: ctg-nct07718126-v1]","field":"Named organizations"},{"after":"name: ctg-nct07718126-v1; aliases: ctg-nct07718126-v1; category: ctg-nct07718126-v1; status: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; summary: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; evidenceNote: journal-pmid-40421736, journal-pmid-41407860, sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025, fda-unapproved-glp1-concerns-2026-r2","before":"name: ctg-nct07718126-v1; aliases: ctg-nct07718126-v1; category: ctg-nct07718126-v1; status: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; summary: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; evidenceNote: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/mazdutide/versions/4/","version":4},"id":"profile:mazdutide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added a plain-language reader guide with cited answers, published trial results from our human evidence review, ClinicalTrials.gov records naming Innovent and Eli Lilly, and FDA’s current page on unapproved GLP-1 drugs, which names mazdutide. The status line keeps its cited China-only wording.","peptideSlugs":["mazdutide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/mazdutide/v3.json","sha256":"25babb046ccc851992c5837f0190ca5ad5b88637872bd6a64294b9bf935c5215"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/mazdutide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-unapproved-glp1-concerns-2026-r2","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","verifiedAt":"2026-11-14"},{"id":"journal-pmid-40421736","name":"The New England Journal of Medicine","sourceClass":"A","title":"Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1, 2025) · PMID 40421736","url":"https://doi.org/10.1056/NEJMoa2411528","verifiedAt":"2026-11-14"},{"id":"sipac-mazdutide-approval-report-2025","name":"Suzhou Industrial Park Market Supervision Bureau","sourceClass":"A","title":"June 27, 2025 government report of Chinese approval for mazdutide weight management","url":"https://www.sipac.gov.cn/szgyyqscjgj/gzdt/202506/a5e5b5345b1b422c84bc7eed401e7df7.shtml","verifiedAt":"2026-09-15"},{"id":"suzhou-mazdutide-indications-report-2025","name":"Suzhou Municipal Government","sourceClass":"A","title":"December 19, 2025 government report describing Chinese mazdutide diabetes and weight indications","url":"https://www.suzhou.gov.cn/szsrmzf/ylfw/202512/0bd9b32d114d4c50b00e7e1860c99b13.shtml","verifiedAt":"2026-09-15"}],"subject":{"slug":"mazdutide","type":"profile"}}
